| Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection CY Wu, YJ Chen, HJ Ho, YC Hsu, KN Kuo, MS Wu, JT Lin Jama 308 (18), 1906-1913, 2012 | 884 | 2012 |
| Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis J Li, B Zou, YH Yeo, Y Feng, X Xie, DH Lee, H Fujii, Y Wu, LY Kam, F Ji, ... The lancet Gastroenterology & hepatology 4 (5), 389-398, 2019 | 839 | 2019 |
| Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial JM Liou, CC Chen, MJ Chen, CC Chen, CY Chang, YJ Fang, JY Lee, ... The Lancet 381 (9862), 205-213, 2013 | 332 | 2013 |
| Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients YC Hsu, JT Lin, HJ Ho, YH Kao, YT Huang, NW Hsiao, MS Wu, YY Liu, ... Hepatology 59 (4), 1293-1302, 2014 | 306 | 2014 |
| Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection YC Hsu, HJ Ho, YT Huang, HH Wang, MS Wu, JT Lin, CY Wu Gut 64 (3), 495-503, 2015 | 242 | 2015 |
| Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis X Tantai, Y Liu, YH Yeo, M Praktiknjo, E Mauro, Y Hamaguchi, ... Journal of hepatology 76 (3), 588-599, 2022 | 201 | 2022 |
| Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial JM Liou, CC Chen, CM Chang, YJ Fang, MJ Bair, PY Chen, CY Chang, ... The Lancet Infectious Diseases 19 (10), 1109-1120, 2019 | 152 | 2019 |
| Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B YC Hsu, TCF Yip, HJ Ho, VWS Wong, YT Huang, HB El-Serag, TY Lee, ... Journal of hepatology 69 (2), 278-285, 2018 | 148 | 2018 |
| Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice ZL Lai, CH Tseng, HJ Ho, CKY Cheung, JY Lin, YJ Chen, FC Cheng, ... Scientific reports 8 (1), 15625, 2018 | 147 | 2018 |
| Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial JM Liou, YJ Fang, CC Chen, MJ Bair, CY Chang, YC Lee, MJ Chen, ... The Lancet 388 (10058), 2355-2365, 2016 | 143 | 2016 |
| Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B TY Lee, YC Hsu, HC Tseng, SH Yu, JT Lin, MS Wu, CY Wu JAMA internal medicine 179 (5), 633-640, 2019 | 136 | 2019 |
| Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria YJ Fang, JM Liou, CC Chen, JY Lee, YC Hsu, MJ Chen, PH Tseng, ... Gut 64 (10), 1517-1528, 2015 | 107 | 2015 |
| Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial JM Liou, CC Chen, CY Chang, MJ Chen, YJ Fang, JY Lee, CC Chen, ... Journal of Antimicrobial Chemotherapy 68 (2), 450-456, 2013 | 106 | 2013 |
| Delayed endoscopy as a risk factor for in‐hospital mortality in cirrhotic patients with acute variceal hemorrhage YC Hsu, CS Chung, CH Tseng, TL Lin, JM Liou, MS Wu, FC Hu, HP Wang Journal of gastroenterology and hepatology 24 (7), 1294-1299, 2009 | 104 | 2009 |
| Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria YC Hsu, JM Liou, SC Liao, TH Yang, HT Wu, WL Hsu, HJ Lin, HP Wang, ... Official journal of the American College of Gastroenterology| ACG 104 (10 …, 2009 | 94 | 2009 |
| Combining hepatitis B core‐related and surface antigens at end of nucleos (t) ide analogue treatment to predict off‐therapy relapse risk YC Hsu, MH Nguyen, LR Mo, MS Wu, TH Yang, CC Chen, CH Tseng, ... Alimentary Pharmacology & Therapeutics 49 (1), 107-115, 2019 | 93 | 2019 |
| Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis CH Tseng, YC Hsu, TH Chen, F Ji, IS Chen, YN Tsai, H Hai, T Hosaka, ... The Lancet Gastroenterology & Hepatology 5 (12), 1039-1052, 2020 | 91 | 2020 |
| Postoperative peg‐interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus‐related hepatocellular carcinoma YC Hsu, HJ Ho, MS Wu, JT Lin, CY Wu Hepatology 58 (1), 150-157, 2013 | 91 | 2013 |
| Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B YC Hsu, GLH Wong, CH Chen, CY Peng, ML Yeh, KS Cheung, H Toyoda, ... Official journal of the American College of Gastroenterology| ACG 115 (2 …, 2020 | 87 | 2020 |
| Off-therapy response after nucleos (t) ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study) G Hirode, HSJ Choi, CH Chen, TH Su, WK Seto, S Van Hees, ... Gastroenterology 162 (3), 757-771. e4, 2022 | 85 | 2022 |
Chun-Ying WuTaipei Veterans General Hospital; National Yang-Ming UniversityBestätigte E-Mail-Adresse bei vghtpe.gov.tw
